104 related articles for article (PubMed ID: 21851539)
1. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
Shore N; Cookson MS; Gittelman MC
BJU Int; 2012 Jan; 109(2):226-32. PubMed ID: 21851539
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
Dineen MK; Tierney DS; Kuzma P; Pentikis HS
J Clin Pharmacol; 2005 Nov; 45(11):1245-9. PubMed ID: 16239357
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
Schlegel PN;
J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
[TBL] [Abstract][Full Text] [Related]
4. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
5. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
Schlegel PN; Kuzma P; Frick J; Farkas A; Gomahr A; Spitz I; Chertin B; Mack D; Jungwirth A; King P; Nash H; Bardin CW; Moo-Young A
Urology; 2001 Oct; 58(4):578-82. PubMed ID: 11597543
[TBL] [Abstract][Full Text] [Related]
6. Histrelin: in advanced prostate cancer.
Deeks ED
Drugs; 2010 Mar; 70(5):623-30. PubMed ID: 20329807
[TBL] [Abstract][Full Text] [Related]
7. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.
Djavan B; Schlegel P; Salomon G; Eckersberger E; Sadri H; Graefen M
Can J Urol; 2010 Aug; 17(4):5265-71. PubMed ID: 20735905
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
9. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
10. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
11. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
12. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
13. [Histrelin acetate--the first once yearly LHRH agonist].
Altarac S
Lijec Vjesn; 2011; 133(9-10):320-2. PubMed ID: 22165080
[TBL] [Abstract][Full Text] [Related]
14. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
15. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.
Woolen S; Holzmeyer C; Nesbitt E; Siami PF
Prostate Cancer; 2014; 2014():490315. PubMed ID: 25548680
[TBL] [Abstract][Full Text] [Related]
18. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
19. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
